Steadybase.

Belite Bio, Inc.

Website LinkedIn
  • BLTE ยท Nasdaq
  • Pharmaceutical Preparations
  • San Diego, CA
  • 41 employees
  • CIK 0001889109

Updated from SEC filings through

Top things to know

Employees41As of December 31, 2025
Next earningsFebruary 11, 2027Estimated from past filings

Executives

Belite Bio, Inc is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in San Diego, CA. It trades as BLTE on Nasdaq. It reported about 41 employees. Yu-Hsin Lin is Chief Executive Officer.

Five-year financials

MetricFY2025FY2024FY2023FY2022FY2021
Revenue Not on file Not on file Not on file Not on file Not on file
Operating income -$84.2M
20-F, 2026-03-31
-$40.0M
20-F, 2026-03-31
-$31.7M
20-F, 2026-03-31
-$12.8M
20-F, 2025-03-17
-$9.8M
20-F, 2024-03-12
SG&A $38.8M
20-F, 2026-03-31
$10.1M
20-F, 2026-03-31
$6.8M
20-F, 2026-03-31
$4.0M
20-F, 2025-03-17
$2.4M
20-F, 2024-03-12
Net income -$77.6M
20-F, 2026-03-31
-$36.1M
20-F, 2026-03-31
-$31.6M
20-F, 2026-03-31
-$12.6M
20-F, 2025-03-17
-$9.7M
20-F, 2024-03-12

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Yu-Hsin Lin Chief Executive Officer Form 4, September 9, 2026
Hao-Yuan Chuang
CFO at Belite Bio
Chief Financial Officer Form 4, September 9, 2026
Hendrik Peter Scholl Chief Medical Officer Form 4, June 22, 2026
Nathan L. Mata Chief Scientific Officer Form 4, May 8, 2026

Shares and governance

Shares outstanding 39.3 million (as of December 31, 2025) 20-F, March 31, 2026
Reportable segments 1 (period ending December 31, 2025) 20-F, March 31, 2026
Auditor Deloitte & Touche (Taipei, Taiwan) Latest 10-K

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
November 12, 2026 Hendrik Peter Scholl
Chief Medical Officer
Sale 2,000 $332K Form 4, November 16, 2026
October 1, 2026 Hendrik Peter Scholl
Chief Medical Officer
Sale 500 $83K Form 4, October 5, 2026
September 8, 2026 Yu-Hsin Lin
Chief Executive Officer
Sale 100,435 $19.1M Form 4, September 9, 2026
September 8, 2026 Hao-Yuan Chuang
Chief Financial Officer
Sale 67,395 $12.8M Form 4, September 9, 2026
August 12, 2026 Hao-Yuan Chuang
Chief Financial Officer
Sale 367 $66K Form 4, August 14, 2026
August 12, 2026 Yu-Hsin Lin
Chief Executive Officer
Sale 365 $66K Form 4, August 14, 2026
June 18, 2026 Hendrik Peter Scholl
Chief Medical Officer
Sale 10,000 $1.5M Form 4, June 22, 2026
June 16, 2026 Hendrik Peter Scholl
Chief Medical Officer
Sale 10,000 $1.4M Form 4, June 17, 2026

Recent 8-K events

No 8-K filings on file.

Frequently asked questions about Belite Bio, Inc

What does Belite Bio, Inc do?
Belite Bio, Inc is classified by the SEC as Pharmaceutical Preparations (SIC 2834). It is based in San Diego, CA.
How many employees does Belite Bio, Inc have?
About 41 as of December 31, 2025, as stated in its annual report.
Who is the CEO of Belite Bio, Inc?
Yu-Hsin Lin, Chief Executive Officer, as named in a 4 filed September 9, 2026.
Who is the CFO of Belite Bio, Inc?
Hao-Yuan Chuang, Chief Financial Officer, as named in a 4 filed September 9, 2026.
Where is Belite Bio, Inc headquartered?
San Diego, CA.
What is Belite Bio, Inc's stock ticker?
BLTE on Nasdaq.
What industry is Belite Bio, Inc in?
Pharmaceutical Preparations, SIC code 2834.
What is Belite Bio, Inc's website?
belitebio.com.
When does Belite Bio, Inc report earnings next?
February 11, 2027. This is an estimate from past filing dates, not a confirmed date.
Is Belite Bio, Inc a public company?
Yes. Belite Bio, Inc files with the SEC under CIK 0001889109 and trades as BLTE.
Who audits Belite Bio, Inc?
Deloitte & Touche, Taipei, Taiwan, as named in its latest annual report (10-K).
How many shares of Belite Bio, Inc are outstanding?
39.3 million shares as of December 31, 2025, from its 20-F filed March 31, 2026.
How many business segments does Belite Bio, Inc report?
1 reportable segment for the period ending December 31, 2025, from its 20-F filed March 31, 2026.
Have Belite Bio, Inc insiders traded stock recently?
Since April 30, 2026, officers and directors reported 14 open-market sales worth about $36.2M and 0 purchases on Forms 4 and 5. The most recent: Hendrik Peter Scholl (Chief Medical Officer) sold 2,000 shares on November 12, 2026.